Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

onabotulinumtoxinA (Toxin type A)

Botox, Botox Cosmetic, Vistabel (UK), Xeomin (UK)

abobotulinumtoxinA (Toxin type A)


incobotulinumtoxinA (Toxin type A)


rimabotulinumtoxinB (Toxin type B)

Myobloc, NeuroBloc (UK)

Pharmacologic class: Neurotoxin

Therapeutic class: Neuromuscular blocker

Pregnancy risk category C

Toxin type A (onabotulinumtoxinA)

Toxin types A and B (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotu-linumtoxinB)

Toxin type A (onabotulinumtoxinA) when administered for eye disorders

Toxin type A (abobotulinumtoxinA)

Toxin type B (rimabotulinumtoxinB)

FDA Box Warning

• Postmarketing reports indicate that the effects of all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects, including asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These signs and symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and deaths have occurred.

• The risk of signs and symptoms is probably greatest in children treated for spasticity, but signs and symptoms can also occur in adults treated for spasticity and other conditions, particularly in patients who have underlying conditions that would predispose them to these symptoms.

• In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at dosages comparable to those used to treat cervical dystonia and at lower dosages.


Blocks neuromuscular transmission by binding to receptor sites on motor nerve terminals and inhibiting acetylcholine release, thereby causing localized muscle denervation. As a result, local muscle paralysis occurs, which leads to muscle atrophy and reinnervation due to development of new acetylcholine receptors.


Toxin type A-(onabotulinumtoxinA)

Powder for injection: 100 units/vial

Toxin type A-abobotulinumtoxinA

Freeze-dried powder for injection: 300 units/vial, 500 units/vial

Toxin type A-(incobotulinumtoxinA)

Powder for injection, lyophilized: 50 units in single-use vials, 100 units in single-use vials

Toxin type B-(rimabotulinumtoxinB)

Solution for injection: 5,000-units/ml vial

Indications and dosages

Toxin type A (onabotulinumtoxinA)

Temporary improvement in appearance of moderate to severe glabellar lines associated with corruga-tor or procerus muscle activity

Adults ages 65 and younger: Botox cosmetic only-Total of 20 units (0.5-ml solution) injected I.M. as divided doses of 0.1 ml into each of five sites: two in each corrugator muscle and one in procerus muscle. Injection usually needs to be repeated q 3 to 4 months to maintain effect. Dysport-50 units I.M. in five equal aliquots of 10 units each to achieve clinical effect

Xeomin-Or, 20 units per treatment session divided into five equal I.M. injections of 4 units each.

Treatment of blepharospasm in patients previously treated with onabotulinumtoxinA (Botox)

Adults: Xeomin-When initiating therapy, base dose, number, and location of injections on the previous dosing of onabotulinumtoxinA (Botox). If previous dose of Botox isn't known, the recommended starting dose is 1.25 to 2.5 units per injection site.

Upper limb spasticity

Adults: Botox-75 to 360 units I.M. divided among selected muscles at a given treatment session. Dose can be repeated no sooner than 12 weeks after the previous injection.

Prophylaxis of headaches in patients with chronic migraine (15 or more days per month with headache lasting 4 hours a day or longer)

Adults: Botox-155 units as 0.1-ml (5 units) injections per each site divided across seven head and neck muscles

Severe axillary hyperhidrosis inadequately managed by topical agents

Adults: Botox-50 units per axilla injected into defined hyperhidrotic area


Adults: 1.25 to 2.5 units injected into medial and lateral pretarsal orbicularis oculi of upper eyelid and lateral pretarsal orbicularis oculi of lower eyelid


Adults: 1.25 to 5 units injected into eyelid (dosage varies with strabismus severity). Dose can be repeated in 7 to 14 days if patient has adequate response; with inadequate response, dosage may be doubled.

Toxin types A and B (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotu-linumtoxinB)

Treatment of cervical dystonia to decrease severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients

Adults: Xeomin-120 units injected I.M. into affected muscles per treatment session.

To relax skeletal muscles and reduce severity of abnormal head position and neck pain associated with cervical dystonia

Adults: Botox-Usual dosage is 236 units injected I.M. locally into affected muscles. Dosage ranges from 198 to 300 units. Dysport-500 units I.M. as a divided dose among affected muscles in patients with or without a history of prior treatment with botulinum toxin.

Myobloc-2,500 to 5,000 units I.M. injected locally into affected muscles.


• Hypersensitivity to drug or its components

• Allergy to cow's-milk protein (Dysport)

• Acute urinary tract infection or acute urinary retention (Botox intradetrusor injections)

• Active infection at injection site


Use cautiously in:

• cardiovascular disease, peripheral neuropathy, neuromuscular disorders, compromised respiratory function, dysphagia

• inflammation at injection site, injections near vulnerable anatomical structures

• pregnant or breastfeeding patient

• children younger than age 12; children younger than age 18 (Dysport, Xeomin)


• Be aware that only trained professional medical personnel should inject this drug.

• Be aware that botulinum toxin products aren't interchangeable.

Toxin type A (onabotulinumtoxinA) when administered for eye disorders

• Reconstitute by slowly injecting preservative-free normal saline solution into drug vial.

• Rotate vial gently to mix drug; then draw up at least 20 units (0.5-ml solution) and expel air bubbles.

• Remove needle used for reconstitution, and attach 30G needle. Then inject drug as divided doses of 0.1 ml into each of five sites (two in each corruga-tor muscle, one in procerus muscle).

• Prepare eye with several drops of local anesthetic and ocular decongestant, as prescribed, several minutes before injection for blepharospasm or strabismus.

• When administering for upper limb spasticity, dilute with preservative-free normal saline solution to 200 units/4 ml or 100 units/2 ml. Then, using a 25G to 30G needle for superficial muscles and a longer 22G needle for deeper musculature, inject no more than 50 units per site.

Toxin type A (abobotulinumtoxinA)

• Reconstitute each 300-unit vial with 0.6 ml preservative-free normal saline solution and each 500-unit vial with 1 ml preservative-free normal saline solution.

• Swirl vial gently to mix drug.

• Remove needle used for reconstitution. Use a 23G to 25G needle for administration. Then inject 10 units into each of five sites (two in each corrugator muscle and one in the procerus muscle).

• Use within 4 hours of reconstitution.

Toxin type B (rimabotulinumtoxinB)

• Draw up prescribed dose from preservative-free, 3.5-ml single-use vial.

• Don't shake vial.

• Divide prescribed dose and inject locally into affected muscles.

Adverse reactions

CNS: headache, dizziness

CV: hypertension, arrhythmias, myocardial infarction (MI)

EENT: blepharoptosis, conjunctivitis, keratitis, eye dryness, double vision, tearing, increased sensitivity to light, sinusitis, pharyngitis

GI: nausea, dyspepsia, difficulty swallowing

Musculoskeletal: back pain, neck pain, muscle weakness

Respiratory: pneumonia, bronchitis, upper respiratory tract infection

Skin: skin tightness, ecchymosis

Other: tooth disorder, injection site redness, edema, or pain, flulike symptoms, facial muscle paralysis, infection, anaphylaxis


Drug-drug. Aminoglycosides, anticholinesterase compounds, clindamycin, lincomycin, magnesium sulfate, other neuromuscular blockers (such as succinylcholine), polymyxin B, quinidine: increased risk of adverse effects

Patient monitoring

• Stay alert for signs and symptoms of anaphylaxis, particularly after first dose.

• Monitor vital signs and ECG, watching for evidence of hypertension, arrhythmias, and MI.

• Assess effect of drug on affected muscles; check for paralysis.

Be aware that spread of toxin effects may lead to swallowing and breathing difficulties and death. Provide immediate medical attention if respiratory, speech, or swallowing difficulties occur.

• Monitor temperature. Watch for signs and symptoms of respiratory and EENT infections as well as flulike symptoms.

Patient teaching

Instruct patient to seek immediate medical attention if respiratory, speech, or swallowing difficulties occur.

• Teach patient about desired effect of injection. Advise patient to report paralysis.

• Instruct patient to report signs and symptoms of infection, particularly flulike illness and EENT and respiratory infections.

• Inform patient being treated for ble-pharospasm (uncontrollable blinking) that he may experience transient eyelid drooping, corneal inflammation, double vision, dry eyes, tearing, and light sensitivity.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A trademark for a preparation of botulinum toxin, used to treat blepharospasms, strabismus, and muscle dystonias and to smooth facial wrinkles.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


Botulinum toxin A, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


A brand name for a powder used to reconstitute a solution of botulinum A toxin complexed with haemagglutinin. This is used to treat a wide and increasing range of conditions. See BOTULINUM TOXIN.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
For migraine relief, 100 units of Botox are injected (20 injections) throughout the head area, including the back of the neck, forehead and temples to block pain receptors.
"Although Botox generally lasts for three to six months, most problems will start to look better after six weeks or so."
The FDA evaluated the drug's safety and efficacy for overactive bladder through two studies in which 1,105 patients were randomly assigned to receive injections of 100 units of Botox (20 injections of 5 units each) or placebo.
Donc, un avis medical est obligatoire pour toute injection de Botox. Pourquoi je dis tout cela ?
It is equally common in men and women and it is a common treatment to go in for Botox, for it gives a good, temporary cure for the season with no side effects," Dr Deepali Bhardwaj, dermatologist, Rockland hospital said.
If they can't even find out if a Botox mom is lying for money, then what else could they have missed?
Botox is a botulin-based drug that smoothes wrinkles by paralyzing facial muscles.
Based on positive Phase III trials announced in September 2008, Allergan has filed for FDA approval of Botox for treatment of chronic migraine and expects the FDA to rule on the application this year.
Two weeks after their first Botox injections, 40 women took an average of about one-quarter of a second longer to read a sentence describing an angry or sad situation than they had before the procedure, Havas and his colleagues found.
Martin Adams, healthcare analyst at Datamonitor, said that a green light from the UK generally augers well for Botox s approval as a migraine treatment throughout the rest of Europe and the US.
Johns Hopkins researchers have found that patients with a painful and debilitating nerve compression disorder called thoracic outlet syndrome (TOS), which studies suggest may occur in up to 8 percent of the population, reported a significant reduction in short-term pain after receiving a single, low-dose injection of Botox in a muscle located in the neck.Though the study, published in the April issue of the journal Pain Medicine, was small, researchers say it suggests Botox is a safe, noninvasive alternative to the syndrome's treatment of last resort: surgery to remove the first rib and sever one of the muscles in the neck."There haven't been many alternatives to the use of surgery to treat this syndrome," says Paul J.